Press releasesicon

Tillotts Pharma: Positive Results of Largest Phase III Clinical Trial of Mesalazine Induction Therapy Published

11th October 2017
Rheinfelden, Switzerland
more »

Tillotts Pharma eröffnet neue Zweiniederlassung in Berlin

23rd February 2017
more »

Tillotts Pharma opens office in Berlin

23rd February 2017
more »

Tillotts Pharma introduces OPTICORE™

18th November 2016
more »

Tillotts’ parent company Zeria receives approval for Zentacort® in Japan

10th October 2016
more »

Tillotts Pharma celebrates 30 years anniversary

6th September 2016
more »

Tillotts Pharma opens in France and celebrates 30 Years anniversary

6th September 2016
more »

Champion der Gastroenterologie in Europa

Original German article and English translation available.

18th September 2015
Basler Zeitung
more »

Tillotts Pharma AG ist auf Expansionskurs

Original German article and English translation available.

2nd July 2015
Regio Aktuell
more »

Many Europeans with mild-to-moderate ulcerative colitis nonadherent to therapy

24th April 2015
Healio Gastroenterology
more »

Pharma’s Future Depends on Patient Adherence

16th April 2015
eyeforpharma
more »

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

17th March 2015
more »

You should know ….. electronically to better communication and increased awareness of patients

11th March 2015
more »

IBD CONGRESS NEWS featured Tillotts Pharma

1st January 2015
more »

Weltweit Nummer eins

27th May 2014
more »

Kleine Pharmafirma ist auf Wachstumskurs

16th May 2014
more »

Kleiner ist besser – Interview mit Dr. Roberto Bravo, Head of Pharmaceutical Development Department

14th April 2014
more »

Media Archive